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Abstract: Transplacental or fetomaternal hemorrhage (FMH) may occur during pregnancy or at 
delivery and lead to immunization to the D antigen if the mother is Rh-negative and the baby is 
Rh-positive. This can result in hemolytic disease of the fetus and newborn (HDFN) in subsequent 
D-positive pregnancies. The aim of this study is to highlight the challenges associated with 
the effective management and prevention of Rh alloimmunization among Rh-negative women 
in Sub-Saharan Africa. In most Sub-Saharan African countries, there is poor and sometimes 
no alloimmunization prevention following potentially sensitizing events and during medical 
termination of pregnancy in Rh-negative women. Information about previous pregnancies and 
termination are often lacking in patients’ medical notes due to poor data management. These 
issues have made the management of Rh-negative pregnancy a huge challenge. Despite the 
fact that the prevalence of Rh-negative phenotype is significantly lower among Africans than 
Caucasians, Rh alloimmunization remains a major factor responsible for perinatal morbidity in 
Sub-Saharan Africa and may result in the compromise of the woman’s obstetric care due to the 
unaffordability of anti-D immunoglobulin. There is the urgent need for the implementation of 
universal access to anti-D immunoglobulin for the Rh-negative pregnant population in Africa. 
Anti-D immunoglobulin should be available in cases of potentially sensitizing events such as 
amniocentesis, cordocentesis, antepartum hemorrhage, vaginal bleeding during pregnancy, 
external cephalic version, abdominal trauma, intrauterine death and stillbirth, in utero therapeutic 
interventions, miscarriage, and therapeutic termination of pregnancy. There is also the need 
for the availability of FMH measurements following potentially sensitizing events. The low-
cost acid elution method, a modification of the Kleihauer–Betke (KB) test, can become a 
readily available, affordable, and minimum alternative to flow cytometric measurement of 
FMH. Knowledge of anti-D prophylaxis among obstetricians, biomedical scientist, midwives, 
traditional birth attendants, pharmacists, and nurses in Africa needs to be improved. This will 
facilitate quality antenatal and postnatal care offered to Rh-negative pregnant population and 
improve perinatal outcomes.
Keywords: rhesus isoimmunization, Sub-Saharan Africa, universal access, anti-D, management, 
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Introduction
The human red blood cell (RBC) membrane is complex and contains a variety of blood 
group antigens, the most clinically significant being the ABO system and the Rh system. 
The Rh system consists of two related proteins, RhD and RhCE, which express the D 
and CE antigens, respectively. People who have the D antigen on their RBCs are said International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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to be RhD-positive, whereas those who do not are said to be 
RhD-negative. If the mother is RhD-negative and the fetus 
RhD-positive, the mother may react to fetal blood cells in 
her circulation by developing anti-D antibodies, a process 
known as RhD sensitization. Sensitization is unlikely to affect 
the current fetus but may result in hemolytic disease of the 
fetus and newborn (HDFN) during a second RhD-positive 
pregnancy. In its mildest form the infant has sensitized RBCs, 
which are detectable only in laboratory tests; however, HDFN 
may result in jaundice, anemia, developmental problems, or 
intrauterine death.1
The frequency of RhD-negative phenotype in previous 
studies in Nigeria 4.44%,2 3.9% in Kenya,3 4.06% in Guinea,4 
and 2.4% in Cameroon.5 These findings are much lower than 
the $14% prevalence of Rh-negative phenotype observed in 
studies among Caucasians.6
In most Sub-Saharan African countries, there are 
challenges associated with Rh pregnancies.7 A previous 
report indicated the effectiveness of anti-D prophylaxis in 
the prevention of HDFN despite poor access.8 The utiliza-
tion rate of anti-Rh antiserum in South African population 
groups for the years 1983–1985 was investigated. The crude 
utilization rate of anti-Rh antiserum was 41%–44% for all 
population groups combined. The rate for Blacks, Whites, 
Indians, and Coloreds was 14%–20%, 89%–94%, 59%–64%, 
and 45%–51%, respectively.9 The potential risk of rhesus 
alloimmunization and the ensuing risk of fetal death with 
increasing parity were investigated in two groups of par-
turients:   primiparous and grand multiparous Mozambican 
parturients. The difference did not reach statistical signifi-
cance.10 A previous report from Zimbabwe indicated that 
anti-D immunoglobulin remains the most important alloan-
tibody causing HDN, regardless of the availability of anti-D 
immunoglobulin for prophylaxis and suggests that all patients 
at booking should have an antibody screen.11 A report from 
Nigeria has shown that isoimmunization due to Rh incompat-
ibility is poorly studied among Nigerian women and indi-
cates the urgent need for a management protocol for anti-D 
immunoglobulin for prophylaxis.12 Care management with 
anti-D prophylaxis in patients presenting with severe alloim-
munization is difficult to access in Sub-Saharan Africa.13 
Beyond the challenge of access to anti-D prophylaxis, there is 
lack of alloimmunization prevention during illegal abortions 
and poor documentation of adequate information in patients’ 
medical notes. These factors are highly responsible for the 
difficult management of Rh-negative patients.14 A cross-
sectional retrospective study to determine the prevalence 
of anti-D immunoglobulin among Cameroonian women of 
reproductive age has indicated an anti-D prevalence of 4% 
among Rh-negative African women.15
To prevent HDFN in most developed countries, RhD-
negative women are given anti-D immununoglobulin (IgG) 
after delivery and often also between 28 and 34 weeks of 
gestation. At delivery, RhD phenotype of the newborn is 
determined even if RhD fetal genotype is known. Maternal 
blood is drawn for quantification of fetomaternal transfusion 
within 72 hours of delivery of a Rh-positive baby and the 
optimum amount of anti-D immunoglobulin administered.16 
Anti-D prophylaxis has significantly reduced the inci-
dence of erythroblastosis fetalis caused by sensitization to 
the D-  antigen and perinatal deaths from alloimmunization 
have fallen 100-fold in the developed world.17,18
The anti-D immununoglobulin is prepared from the 
plasma of immunized human donors and therefore exists 
in limited supply. Monoclonal anti-D antibodies have been 
developed to replace polyclonal anti-D and in vivo assays 
for these have been predominantly based on their ability to 
clear erythrocytes from the maternal circulation.19 Although 
the implementation of a program of routine antenatal anti-D 
prophylaxis (RAADP) has led to a significant decline in the 
residual numbers of women becoming sensitized in most 
developed countries, a significant number of women are 
not fortunate enough to have access in Sub-Saharan Africa 
and thus continue to be affected. This is an ethical issue of 
utmost public health importance. The aim of this study is 
thus to highlight the challenges associated with the effective 
management and prevention of Rh alloimmunization among 
Rh-negative women in Sub-Saharan Africa.
Anti-D immunoglobulin
Anti-D immunoglobulin is produced by the pooling and 
fractionation of plasma from large numbers of donors who 
themselves are RhD-negative and have been exposed to 
RhD-positive RBCs to stimulate the production of RhD 
antibodies.20,21 The future of anti-D immunoglobulin might 
involve monoclonal or recombinant products, thus eliminating 
the risks associated with human blood products. Costs would 
probably increase if recombinant products were used.22 
Anti-D, a polyclonal IgG product, is routinely and effectively 
used to prevent HDFN. The mechanism of anti-D has not 
been fully elucidated. However, a correlation has frequently 
been observed between anti-D-mediated RBC clearance and 
prevention of the antibody response, suggesting that anti-D 
may be able to destroy RBCs without triggering the adaptive 
immune response. Anti-D opsonized RBCs may also elicit 
inhibitory FcgammaRIIB signaling in B cells and prevent International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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B cell activation. The ability of antigen-specific IgG to inhibit 
antibody responses has also been observed in a variety of 
animal models immunized with a vast array of different 
antigens, such as sheep RBCs. This effect has been referred 
to as antibody-mediated immune suppression.23
Antenatal antibody screening
It is recommended that all women in most developed countries 
should have a blood group and antibody screening at first 
antenatal visit. It has been reported that 1.5%–2% of pregnant 
women show atypical blood group sensitization.24 Opinion 
is divided as to the clinical importance of a repeat anti-D 
antibody screen at 28 weeks’ gestation. Those in support of 
28 weeks’ testing argue that there is the potential advantage 
to identify about 0.18% or fewer women particularly 
Rh-negative who become alloimmunized after their first 
antenatal screen possibly as a result of potential sensitizing 
event occurring after the first antenatal visit.25
The American Society of Clinical Pathology recommends 
that testing for unexpected antibody be carried out before 
antenatal anti-D is given to Rh-negative pregnant women 
and that repeat Rh testing be omitted if two documented 
test results confirming the Rh-negative status of the woman 
are on her record.26 Prior to 1970, HDFN due to anti-D was 
a significant cause of morbidity and mortality. By 1990, a 
reduction in mortality from 1.2 per 1000 births to 0.02 per 
1000 births had been achieved in response to the introduction 
of immunoprophylaxis with anti-D immunoglobulin.27 At that 
time the sensitization rate dropped to about 1.2%. A further 
reduction to between 0.17% and 0.28% was achieved by intro-
ducing prophylaxis during the third trimester of pregnancy.28 
These findings contributed to the National Institute for Clini-
cal Excellence (NICE) recommendation that all D-negative 
pregnant women who do not have immune anti-D should be 
offered anti-D immunoglobulin routinely during the third 
trimester of pregnancy.29 In 2002 the NICE in the United 
Kingdom assessed the cost effectiveness of routine ante-
natal anti-RhD prophylaxis with anti-D immunoglobulin.29 
Previously anti-D immunoglobulin had been administered 
antenatally only when events occurred that would be associ-
ated with a feto-maternal hemorrhage. NICE recommended 
that all RhD negative pregnant women should be offered 
anti-D immunoglobulin at 28 and 34 weeks’ gestation. In 
a predominantly White population, however, about 38% of 
these women are likely to be carrying an RhD-negative fetus 
and would receive the treatment unnecessarily. Consequently, 
NICE also endorsed studies into the feasibility of mass fetal 
blood group by analysis of fetal DNA in maternal plasma. 
The benefits of this testing would be twofold. Firstly, there 
would be a substantial reduction in the use of anti-RhD 
immunoglobulin, an expensive blood product in short supply. 
Secondly, women with an RhD-negative fetus would be 
spared unnecessary exposure to this pooled human blood 
product with its associated discomfort and perceived risk from 
viral or prion contamination.30 Paternal testing of a baby’s 
father may be offered to all Rh-negative pregnant women to 
eliminate unnecessary blood product administration. Mitchell 
and colleagues suggest that if the pregnant woman volunteers 
and confirms in private that her partner is indeed the biological 
father, and if the said father is documented to be a confirmed 
Rh-negative, then anti-D may be omitted.31 However it is 
recommended that partners of Rh-negative pregnant women 
should be routinely tested without this private confirmation. 
This may avoid creating the potential of a possible conflict 
for the pregnant woman between privacy in the relationship 
and the well-being of the fetus. It is being suggested that the 
most important application of blood group genotyping by 
molecular genetics is the prediction of fetal RhD phenotype 
in pregnant women who are Rh-negative and in pregnant 
women with anti-D, in order to assess the risk of HDFN. 
This diagnostic test performed on cell-free fetal DNA in the 
maternal plasma is now available in some laboratories.32 There 
are, however, no national guidelines, which are required to 
call it a routine procedure at a national level. High-throughput 
modifications of this form of fetal D-typing would be valuable 
for testing fetuses of all D-negative pregnant women to avoid 
unnecessary antenatal treatment with anti-D immunoglobulin 
in the 40% of D-negative pregnant women with a D-negative 
fetus. The results of trials in Bristol and Amsterdam33 suggest 
that such routine testing is feasible and accurate. Similarly 
Finning et al34 recommends that high-throughput RhD geno-
typing of fetuses in all RhD-negative women is feasible and 
would substantially reduce unnecessary administration of 
anti-RhD immunoglobulin to RhD-negative pregnant women 
with an RhD-negative fetus.
Organized preventive screening programs for antenatal 
care were first introduced in Western Europe in the twenti-
eth century with the hope that routine antenatal care would 
contribute to a reduction in maternal and infant mortality 
rates. Figures on maternal mortality in the developed world 
show that the risk of death as a result of pregnancy and child 
birth is approximately 1 in 7000 compared with 1 in 23 for 
women living in parts of Africa where antenatal care is poor 
or sometimes nonexistent.35
It is part of modern antenatal care to give all RhD-
negative pregnant women an anti-RhD immunoglobulin International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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IgG injection at about 28 weeks’ gestation with or without 
a booster at 34 weeks’ gestation. This reduces the effect of 
the vast majority of sensitizing events which mostly occur 
after 28 weeks’ gestation. Anti-RhD immunoglobulin is also 
given to non-sensitized Rh-negative women immediately 
within 72 hours after potentially sensitizing events that 
occur during pregnancy. All these advances in antenatal 
management of Rh-negative pregnant women in developed 
countries are beyond the reach of a vast majority of women 
in Sub-Saharan Africa. In most Sub-Saharan African coun-
tries, the recommendation is that women should have an 
ABO and Rh blood group test done at the time of antenatal 
booking. Women found to be Rh-negative and who are 
married to Rh-positive men and run the risk of carrying an 
Rh-positive fetus and who can afford treatment are offered 
prophylactic D immunoglobulin of 500 IU at 28 weeks’ 
gestation. Tests to determine the presence of clinically sig-
nificant alloantibodies in antenatal care patients are seldom 
carried out in most settings. At delivery the blood group of 
the baby is determined. If the baby is found to be Rh-positive, 
500 IU of D immunoglobulin is administered. Facilities for 
determination of FMH are seldom available in most settings. 
Provision of prophylactic D immunoglobulin following 
potential sensitizing events during pregnancy is only avail-
able in an insignificant number of Rh-negative women due 
to unaffordability. The net result is that anti-D remains the 
most important alloantibody causing HDFN in Sub-Saharan 
Africa despite the availability of anti-D immunoglobulin for 
prophylaxis. Only in an insignificant number of centers do Rh 
D-negative women have an antibody screen at booking and 
repeat antibody screens during the rest of their pregnancy.
Rh-negative women should be given an injection of 
human anti-D immunoglobulin after the termination of 
pregnancy procedure to prevent blood incompatibility com-
plications in future pregnancies. However, unsafe abortion, 
defined by the World Health Organization as a procedure for 
terminating an unwanted pregnancy either by persons lacking 
the necessary skills or in an environment lacking the minimal 
medical standards, or both, is prevalent and continues to 
put Rh-negative women who cannot afford anti-D immuno-
globulin at risk of Rh isoimmunization.36 A broad array of 
personnel perform unsafe termination of pregnancy in Africa. 
Aside from the woman herself, others include physicians 
working at clandestine sites or in hospital operating theaters 
after normal working hours. Others with medical experience 
include midwives, traditional birth attendants, pharmacists, 
and nurses. Most worrisome are ‘untrained quacks’ whose 
motives may be financial and their skills negligible. Women 
who are Rh-negative should be given an injection of human 
anti-D immunoglobulin after the termination of pregnancy 
procedure unless the father of the fetus is also Rh-negative. 
This prevents blood incompatibility complications in future 
pregnancies.37
The costs associated with providing routine antenatal 
anti-D prophylaxis are the cost of the anti-D   immunoglobulin 
IgG and the cost of treatment administration. The price of 
anti-D Immunoglobulin differs according to its manufacturers: 
Bio Products Laboratory (BPL; Elstree, UK) offers anti-D 
IgG at a unit price of £27 (US$41) for 500 IU vial38 while 
Baxter Healthcare (Deerfield, IL) anti-D IgG is offered at a 
unit price of £23.90 (US$36) for a 1250 IU vial.39   Offering 
antenatal anti-D prophylaxis will cost an Rh-negative woman 
£47.80 (US$72) to £54 (US$82) per pregnancy depending on 
whether she is administered the BPL or Baxter product at 28 
and 34 weeks. Cost-effective analysis indicates that offering 
routine antenatal anti-D prophylaxis to RhD-negative women 
is economical and results in a marked impact upon the death 
rate associated with hemolytic disease of the newborn.40 Drug 
manufacturers need to be more humane by reducing the cost 
of providing anti-D prophylaxis   particularly in low-income 
countries in Sub-Saharan Africa. Cost constraints have 
remained a limiting factor preventing people from access 
to best possible treatment and care in Sub-Saharan African 
countries like their counterparts in most developed countries. 
There is also the urgent need for African leaders to take up 
the bold challenge to provide   universal access to anti-D pro-
phylaxis for Rh-negative women. Per capita income in most 
settings is Sub-Saharan Africa is low and continues to affect 
affordability to prophylactic anti-D treatment.
In the absence of anti-D prophylaxis to prevent incidence 
of HDFN, options such as exchange blood transfusion and 
intrauterine transfusion (IUT) can significantly reduce 
mortality and prevent stillbirths. However, safety of blood 
and blood products remains a great concern. One of the 
biggest challenges to blood safety particularly in Sub-Saharan 
Africa is accessing safe and adequate quantities of blood 
and blood products. Societies in Africa face several endur-
ing challenges: chronic blood shortages, high prevalence of 
transfusion-transmissible infection, absence of national blood 
transfusion service, recruitment and retention of voluntary 
non-remunerated donors, lack of appropriate infrastructure, 
trained personnel, and financial resources to support the 
running of a safe blood transfusion service.41 Although not 
available in most settings in Sub-Saharan Africa, the intro-
duction of ultrasonographically guided IUT has improved the 
ability to treat severely anemic fetuses earlier in gestation International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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and has increased the chances of survival of more severely 
affected fetuses with the potential for poor neurodevelop-
mental outcomes.42 Around 10%–12% of fetuses affected 
by HDN will require IUT and a relatively high proportion 
of IUT survivors may suffer neurodevelopmental problems 
such as cerebral palsy, deafness, and motor and speech delay 
that will require specialist input and, in some cases, special 
education; others will suffer some degree of developmental 
delay requiring physiotherapy or speech therapy.43
Antepartum and postpartum 
prophylaxis
Current guidelines in the United Kingdom recommend that a 
minimum of 500 IU anti-D IgG be offered to all non-  sensitized 
RhD-negative women at 28 and 34 weeks gestation in order 
to prevent the risk of RhD sensitization in pregnancy.44 It 
is recommended that a minimum anti-D immunoglobulin 
of 250 IU be administered after miscarriage or threatened 
abortion or induced abortion, ectopic pregnancy, following 
chorionic villous sampling, amniocentesis, cordocentesis, 
placental abruption, blunt trauma to the abdomen, placenta 
previa with bleeding, external cephalic version, and any 
other potentially sensitizing events at less than 20 weeks 
gestation in non-sensitized D-negative women. However in 
the event of any sensitizing event after 20 weeks’ gestation, 
a minimum of 500 IU of anti D is administered and blood is 
tested for FMH and if the estimated fetal bleed is greater than 
4 mL, additional anti-D is administered (125 IU per 1 mL 
bleed). Before termination of pregnancy, blood type and 
antibody screen is done and if lady or mother is a confirmed 
RhD-negative 250 IU of anti D is given. A previous report45 
in England had investigated the clinical effectiveness and 
cost-effectiveness of RAADP for RhD-negative women. 
Results showed that RAADP reduces the incidence of sensi-
tization and hence of hemolytic disease of the newborn. The 
economic model suggests that RAADP given to all RhD-
negative pregnant women is likely to be cost-effective at a 
threshold of around £30,000 per quality of life years (QALY) 
gained. The total cost of providing RAADP to RhD-negative 
primigravidae in England and Wales is estimated to be around 
£1.8–3.1 million per year, depending upon regimen, and to 
all RhD-negative pregnant women in England and Wales 
around £2–3.5 million.
In France, targeted prophylaxis is applied regardless of the 
gestational age and a dose of 100 g anti-D immunoglobulin is 
usually enough (200 g is the lowest dosage currently avail-
able). However it is recommended to quantify the volume 
of FMH to avoid administration of a dose of anti-D IgG less 
than 20 g/mL of fetal RBCs. Efficacy of prophylaxis relies 
also on the delay of less than 72 hours between the sensitizing 
event and the injection of anti-D. Intravenous administration 
(IV) of anti-D allows for the immediate neutralization of 
D-positive fetal RBCs and should be, if possible, preferred 
to intramuscular administration (IM).46
In Canada, it is recommended that anti-D immunoglobulin 
300 µg IM or IV should be given within 72 hours of delivery 
to a postpartum non-sensitized Rh-negative woman delivering 
an Rh-positive infant. Additional anti-D immunoglobulin may 
be required for FMH greater than 15 mL of fetal RBCs (about 
30 mL of fetal blood). If anti-D immunoglobulin is not given 
within 72 hours of delivery or other potentially sensitizing 
event, anti-D immunoglobulin should be given as soon as 
the need is recognized, for up to 28 days after delivery or 
other potentially sensitizing events. Anti-D immunoglobulin 
300 µg should be given routinely to all Rh-negative non-
sensitized women at 28 weeks’ gestation when fetal blood 
type is unknown or known to be Rh-positive. Alternatively, 
2 doses of 100–120 µg may be given (120 µg being the lowest 
currently available dose in Canada): one at 28 weeks and one 
at 34 weeks. All pregnant women (D-negative or D-positive) 
should be typed and screened for alloantibodies with an indirect 
antiglobulin test at the first prenatal visit and again at 28 weeks. 
When paternity is certain, Rh testing of the baby’s father may 
be offered to all Rh-negative pregnant women to eliminate 
unnecessary blood product administration. Non-sensitized 
D-negative women are given a minimum anti-D of 120 µg after 
miscarriage or threatened abortion or induced abortion during 
the first 12 weeks of gestation, ectopic pregnancy at less than 
12 weeks’ gestation, molar pregnancy, and following chorionic 
villous sampling. After 12 weeks’ gestation, they should be 
given 300 µg. At therapeutic termination of pregnancy, blood 
type and antibody screen is done unless results of blood type 
and antibody screen during the pregnancy are available, in 
which case antibody screening need not be repeated. Anti-D 
of 300 µg is given to all non-sensitized D-negative women, 
following amniocentesis, placental abruption, blunt trauma to 
the abdomen, cordocentesis, placenta previa with bleeding, 
external cephalic version, and placenta previa with bleeding. 
There is a substantial risk of FMH over 30 mL with such 
events, especially with blunt trauma to the abdomen. If FMH 
is in excess of the amount covered by the dose given (6 mL 
or 15 mL fetal RBC), 10 µg additional anti-D should be given 
for every additional 0.5 mL fetal RBCs.18
A report on Dutch women that evaluated the acceptance 
by pregnant women in a perinatal screening program 
showed that women highly accept the program for prenatal International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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screening for RBC antibodies.47 Similarly a nationwide 
Dutch antenatal study evaluated the risk factors for RhD 
immunization in pregnancy, despite adequate antenatal and 
postnatal anti-D prophylaxis in the previous pregnancy in a 
bid to generate evidence for improved primary prevention 
by extra administration of anti-D immunoglobulin in the 
presence of a risk factor. The report indicated that in at least 
half of the failures of anti-D immunoglobulin prophylaxis, a 
condition related to increased FMH and/or insufficient anti-D 
immunoglobulin administration was observed. The authors 
suggested that RhD immunization may be further reduced by 
strict compliance to guidelines for determination of FMH and 
anti-D immunoglobulin prophylaxis adjusted accordingly, or 
by routine administration of extra anti-D immunoglobulin 
after a non-spontaneous delivery and/or a complicated or 
prolonged third stage of labor.48
Facilities for the determination of FMH to allow for 
optimum dosing of anti-D immunoglobulin are often lacking 
in most settings in Africa. Countries in Sub-Saharan Africa 
could learn from good practices in developed countries to help 
reduce the incidence of Rh isoimmunization and hemolytic 
disease of the newborn. The proposal to use human Anti-D 
immunoglobulin prophylactically in pregnancy should not 
detract from the most expedient approach to further the 
  reduction of Rh disease; that is, to ensure that every eligible 
woman is given Anti-D immunoglobulin after delivery, 
abortion, and other potentially sensitizing events like their 
counterparts in the developed world. Family planning by 
Rh-negative women at risk has the potential to limit the 
number of pregnancies in women already immunized. This is 
likely to be an effective way to reduce the current incidence 
of hemolytic disease in Sub-Saharan Africa. Present evidence 
shows that blanket antepartum Anti-D immunoglobulin 
prophylactic treatment may be very costly but beneficial to 
a significant number of women who may not be fortunate 
enough to have access as a result of unaffordability. There is 
need for sensitive and practical laboratory testing for FMH 
to be clinically available to provide new data on FMH. It is 
suggested that the KB testing should become the minimal 
cost-effective alternative to flow cytometric testing of FMH 
in low-income countries in Sub-Saharan Africa because of 
the cost implication of procuring flow cytometric equipment 
and lack of trained personnel. There is the urgent need for 
pregnant women truly at risk for Rh isoimmunization to be 
identified by analysis of their blood during first antenatal visit 
and that this should become the rational basis for antepartum 
Anti-D immunoglobulin treatment. There are compelling 
advantages in cost, risks, and benefits for an approach of 
selective antepartum Anti-D immunoglobulin therapy as 
opposed to routine prophylaxis for all Rh-negative gravid 
women.49 The knowledge of anti-D prophylaxis among obste-
tricians can be improved. A continual system of education to 
raise awareness of evidence-based practices as well as clini-
cal audit can be implemented to address this.50 Rh-negative 
women in Sub-Saharan Africa will benefit immensely from 
programs such as the RAADP, but costs remains a major 
hindrance.
Testing for FMH
The KB test is a blood test used to measure the amount 
of fetal hemoglobin transferred from a fetus to a mother’s 
bloodstream.51 It is usually performed on Rh-negative moth-
ers to identify women with a large fetomaternal hemorrhage 
(.4 mL of packed fetal RBCs) who may need additional 
anti-D immunoglobulin to ensure complete clearance of all 
fetal RBCs from maternal circulation and thus prevent them 
from being sensitized to produce immune antibodies against 
D- antigen on the surface of the fetal RBCs. A standard dose 
of 125 IU is the required dose of Anti-D immunoglobulin 
required to inhibit 1 mL bleed of fetal RBCs and thus prevent 
the formation of Rh- antibodies in the mother and prevent 
Rh- disease in future Rh-positive children. The KB test is 
the standard method of detecting FMH. It takes advantage of 
the differential resistance of fetal hemoglobin to acid elution. 
A standard blood smear is prepared from the mother’s blood, 
and exposed to an acid bath. This removes adult hemoglobin, 
but not fetal hemoglobin, from the RBCs. Subsequent stain-
ing with eosin makes fetal cells (containing fetal hemoglobin) 
appear rose-pink in color, while adult RBCs are only seen as 
‘ghosts’. A large number of cells (.5000) are counted under 
the microscope and a ratio of fetal to maternal cells generated. 
In those with positive tests, follow-up testing as a postpartum 
check should be done to rule out the possibility of a false 
positive. This could be caused by a process in the mother 
which causes persistent elevation of fetal hemoglobin, for 
example; sickle cell trait and hereditary persistence of fetal 
hemoglobin (HPFH). Comparison with other more expensive 
or technologically advanced methods such as flow cytometry 
has shown that the KB test, like the more advanced methods, 
is sensitive for the detection of FMH.52 Background counting 
errors can result in estimates of as much as 5 mL fetal blood 
loss when there actually is no such blood loss, but standard 
methods available in most laboratories admit an extremely 
low probability of the return of a false positive when more 
severe FMH has taken place. Performance indicators for 
the KB test during antepartum period in most developed International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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  countries include: unexpected/unexplained still birth, signifi-
cant maternal abdominal trauma, post 20 weeks’ gestation 
vaginal bleed, post 20 weeks’ therapeutic termination of 
pregnancy, miscarriage, in utero therapeutic interventions, 
external cephalic version, and antepartum hemorrhage.53 
Testing at the time of birth and postpartum is indicated if 
baby is Rh-positive. A cord sample is collected from all 
babies born of Rh-negative mothers. Where the cord sample 
is Rh(D)-positive, a KB or flow cytometric determination 
of FMH is carried out and anti-D immunoglobulin optimal 
to clear the volume of FMH is administered preferably 
within 72 hours of delivery.54 If recurrent uterine bleeding 
occurs in a D-negative woman after 20 weeks’ gestation, 
anti-D immunoglobulin will be required at a minimum of 
6-weekly intervals. An FMH test should be performed every 
2 weeks and if FMH is detected, additional anti-D will be 
required.55
Since fetal and maternal blood cells have the same life 
expectancy in the maternal bloodstream, it is possible to 
obtain informative results from a KB stain for a fair period 
of time after a stillbirth. However, if the mother and fetus 
are ABO incompatible, it is more crucial to quickly perform 
the KB stain following a stillbirth, as the fetal RBCs will 
be eliminated from the maternal bloodstream very quickly, 
causing the KB stain to underestimate the degree of FMH, 
if any. The KB technique, based on acid elution of maternal 
RBCs, is the most widely used technique in the developed 
world for estimating the volume of FMH and for determining 
the need for additional doses of anti-D immunoglobulin to 
prevent maternal alloimmunization.56 Finally, anything that 
causes persistence of fetal hemoglobin in maternal blood 
cells will make interpretation much trickier. Certain hemo-
globinopathies, the most common of which is sickle cell trait, 
and HPFH do this. The KB test has been used worldwide 
since the 1950s to quantify the FMH and to ensure that an 
appropriate dose of anti-D immunoglobulin is administered 
both antenatally and postnatally to RhD-negative women to 
prevent Rh alloimmunization.16 Although apparently a simple 
test to perform, recent reports have suggested that unless 
meticulous attention is paid to both technique and interpreta-
tion, the accuracy of the test cannot be guaranteed and that it 
should be replaced with a flow cytometric test which would 
give more relevant and accurate results.57 Flow cytometers 
are not, however, available to all laboratories performing esti-
mations of FMH. The comparability of results was assessed 
using a standardized KB technique with flow cytometry with 
a total of 957 samples were analyzed. Results suggest that 
if careful attention is paid to performing a standardized KB 
test, then it is of value in estimating the size of FMH, and 
that flow cytometry may be of additional value for cases in 
which the Kleihauer result is equivocal or indicates that a 
large FMH has occurred which requires the administration 
of additional anti-D immunoglobulin.57 Similarly Johnson 
and colleagues58 evaluated an indirect immunofluorescence 
flow cytometry technique in a series of patients with large 
FMH. Patient samples identified by KB testing as having 
FMH . 4 mL were sent for flow cytometric analysis. The 
report indicated that flow cytometry is helpful for the accurate 
quantification and management of patients with large FMH, 
and in cases where the presence of maternal hemoglobin 
F-containing cells renders the KB technique inaccurate, 
worthwhile reductions in the use of anti-D immunoglobulin 
can be achieved.59
Discussion
Despite the fact that the prevalence of Rh-negative phe-
notype is significantly lower among Africans than in 
  Caucasians, alloimmunization to RhD remains a major 
factor in perinatal morbidity and continues to compromise 
women’s obstetric care in Sub-Saharan Africa due to the 
unaffordability of anti-D immunoglobulin. A preliminary 
study of 67 RhD-  negative women over a 2-year period in 
Nigeria has shown that isoimmunization due to Rh incom-
patibility is poorly studied among Nigerian women, with 
many questions unanswered, and that there is an urgent 
need for a management protocol for this condition, which 
will include both the clinicians and the laboratory biomedi-
cal scientist.12 Similarly a previous report in Cote d’Ivoire 
has indicated that the lack of alloimmunization prevention 
during illegal abortions and the lack of information about 
patients’ medical files are highly responsible for the difficult 
management of Rh-negative patients.13 There are several 
possible reasons for   continuing cases of Rh isoimmunization 
among the Rh-negative   pregnant population in Sub-Saharan 
African: cost of procuring anti-D immunoglobulin; absence 
of a universal access program for all Rh-negative women; 
failure to recognize potential sensitizing events in pregnancy 
as such and to treat them appropriately; failure and absence 
of facilities to assess the extent of FMH; poor and some-
times absence of alloimmunization prevention during illegal 
termination of pregnancy in Rh-negative women; a dearth 
of information about previous pregnancies and termination 
in patients’ medical files due to poor data management; 
failure to   comply with postpartum prophylaxis guidelines 
to offer further anti-D immunoglobulin to all Rh-negative 
women delivered of Rh-positive babies with 72 hours of International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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delivery depending on the extent of FMH; failure to offer Rh-
negative pregnant women anti-D immunoglobulin   following 
any potentially sensitizing event during pregnancy; and 
failure of obstetrician to offer these Rh-negative women 
the maximum standard of antenatal and postnatal care. 
Antenatal management of Rh-negative pregnant women in 
Sub-Saharan Africa is suboptimal. There are several health 
system challenges: socioeconomic realities, lack of adequate 
qualified staff, inadequate referral services, shortage of sup-
plies, and shortages of midwives, counselors, laboratory, and 
obstetrics and gynecology personnel. In the midst of these 
challenges, anti-D remains the most important alloantibody 
causing HDN in Sub-Saharan Africa.11 Evidence has shown 
that prophylaxis of the alloimmunization to the antigen D 
is effective among Rh-negative African women fortunate 
enough to have access.60 Investment in health infrastruc-
ture, personnel, and research both for innovation and to 
improve implementation as well as universal access to anti-D 
immunoglobulin is what countries in Sub-Saharan Africa 
desperately need to facilitate the reduction in the incidence 
of Rh isoimmunization.61 Innovative low-cost devices and 
diagnostic methods such as the use of the KB test for deter-
mination of FMH could improve the quality of care offered 
these women.62 Improving the uptake of quality antenatal, 
intrapartum, and postpartum care as well as innovative 
community-based strategies, combined with health systems 
strengthening and the development of an evidenced-based 
protocol for the management of Rh isoimmunization, are 
critical for evidence-based interventions required to deliver 
interventions to improve screening and treatment for risk 
factors and reduce the risks of Rh isoimmunization.
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